BOLT vs MA · rev $7.7M vs P/E 38, rev $32.79B
Bolt Biotherapeutics (BOLT) versus Mastercard Inc (MA) — a side-by-side from cached financials, not a winner call.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
Mastercard Inc (MA) is a credit services company listed on US. It is led by Michael Miebach.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
Latest reported MA revenue for 2025-12-31 was $32.79B. Net income was $14.97B. Revenue was up 16.4% from 2024-12-31 to 2025-12-31. MA currently screens at market cap $515.12B and trailing P/E 38.4.
BOLT currently screens at market cap $11.3M. MA currently screens at market cap $515.12B and trailing P/E 38.4.
Not investment advice. Open the BOLT and MA stock pages for the full models.
Not investment advice.